Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Hepatitis A Virus Plasma Donors, United States

ABSTRACT: Hepatitis A Virus Incidence Rates and Biomarker Dynamics for Plasma Donors, United States

PROVIDER: PRJEB48304 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Hepatitis E virus surveillance in blood donors in Switzerland

Project description:Hepatitis E virus surveillance in blood donors in Switzerland

| PRJEB47030 | ENA

Gene expression profiles of liver sinusoidal Vγ9+Vδ2+ T cells from healthy donors and patients with hepatitis B virus-related chronic liver disease

Project description:We report the gene expression profiles of liver sinusoidal Vγ9+Vδ2+ T cells from healthy donors and patients with hepatitis B virus-related chronic liver disease.

2021-01-06 | GSE164266 | GEO

Trends in Discard of Kidneys from Hepatitis C Viremic Donors in the United States.

Project description: Not available

| S-EPMC7863640 | biostudies-literature

2 years screening of blood donors for Hepatitis E virus in Switzerland

Project description:2 years screening of blood donors for Hepatitis E virus in Switzerland

| PRJEB47032 | ENA

Quantitative Proteomic Analysis of Plasma Samples from Chronic Hepatitis B and Chronic Liver Failure Patients for Biomarker Discovery

Project description:Hepatitis B virus (HBV)-associated acute on chronic liver failure (HBV-ACLF), characterized by an acute deterioration of liver function in the patients with chronic hepatitis B (CHB), is lack of predicting biomarkers for prognosis. To explore potential biomarkers of HBV-ACLF for clinical applications, immuno-depletion of high-abundance plasma proteins followed by iTRAQ-based quantitative proteomic approach was employed to analyze plasma samples from 20 healthy control people, 20 CHB patients and 20 HBV-ACLF patients, respectively. As a result, a total of 427 proteins were identified and quantified from these samples, and 42 proteins were differentially expressed in HBV-ACLF patients as compared to both CHB patients and healthy controls. According to bioinformatics analysis results, 6 proteins related to immune response (MMR), inflammatory response (OPN, HPX), blood coagulation (ATIII) and lipid metabolism (APO-CII, GP73) were selected as biomarker candidates. Further ELISA analysis confirmed the significant up-regulation of GP73, MMR, OPN and down-regulation of ATIII, HPX, APO-CII in HBV-ACLF plasma samples (p<0.01). Moreover, receiver operating characteristic (ROC) curve analysis revealed high diagnostic value of these candidates in assessing HBV-ACLF. In conclusion, present quantitative proteomic study identified 6 novel HBV-ACLF biomarker candidates and might provide fundamental information for development of HBV-ACLF biomarker.

2018-10-23 | PXD007975 | Pride

Consent to Receive Offers for Kidneys From Donors With Hepatitis C Among Pediatric Kidney Transplant Candidates in the United States.

Project description: Not available

| S-EPMC12558682 | biostudies-literature

Integrative proteomics and transcriptomics identify novel fibrosis-related biomarkers of patients with post-HBV hepatitis cirrhosis

Project description:Background: Hepatitis B virus (HBV) infection is an important public health burden. Chronic HBV infection always leads to chronic hepatitis, liver fibrosis and increases the incidence of liver cancer. However, the mechanism of liver fibrosis caused by persistent HBV infection remains unclear. Methods: In present study, we isolated and enriched primary human hepatic stellate cells (HSCs) from chronically HBV infected patients with liver cirrhosis. The differences expression of mRNA and protein were analyzed by combining proteomics, transcriptomics, and biological network analysis. Results: After bioinformatics analysis with transcriptomics and proteomics data, a total of 2,156 genes and 711 proteins were differently expressed between the liver cirrhosis group and control group. GO enrichment analysis and KEGG analysis indicated those differently expressed molecules were mainly involved in oxidative stress, glycometabolism, and fibrous repair. Moreover, a total of 110 overlapping biomarker were identified and two of them (PKM2 and EHD2) were validated as candidates correlated with liver fibrosis by qRT-PCR and immunofluorescence from primary human HSCs and in vitro cellular hepatic fibrosis model. Conclusion: Our results indicated that PKM2 and EHD2 were overexpressed in chronically HBV infected patients with liver cirrhosis, suggesting them as potential biomarkers and therapeutic targets for liver fibrosis.

2025-12-13 | GSE221083 | GEO

Plasma Protein Signatures in Alcoholic Hepatitis

Project description:Supporting plasma proteomic data from clinical patients with alcoholic hepatitis in comparison to relevant controls and across treatment time points, baseline, 28/29 days, 12 weeks. Samples were digested with trypsin, labeled with TMT 10-Plex, then analyzed by LC-MS/MS. Data was searched with MS-GF+ using PNNL's DMS Processing pipeline.

2019-11-01 | MSV000084528 | MassIVE

The expression of circular RNAs in the plasma from five hepatocellular carcinoma patients and five chronic hepatitis B patients

Project description:Using CapitalBio Technology Human CircRNA Array v2 (4x180K) microarray, we compared the expression of circular RNAs in the plasma from five hepatitis B virus-related hepatocellular carcinoma patients and five chronic hepatitis B patients.

2019-08-15 | GSE135806 | GEO

Gene-expression profiles of hepatitis C-related, early-stage liver cirrhosis

Project description:BACKGROUND & AIMS: Cirrhosis affects 1% to 2% of the world population and is the major risk factor for hepatocellular carcinoma (HCC). Hepatitis C cirrhosis-related HCC is the most rapidly increasing cause of cancer death in the United States. Noninvasive methods have been developed to identify patients with asymptomatic early-stage cirrhosis, increasing the burden of HCC surveillance, but biomarkers are needed to identify patients with cirrhosis who are most in need of surveillance. We investigated whether a liver-derived 186-gene signature previously associated with outcomes of patients with HCC is prognostic for patients with newly diagnosed cirrhosis but without HCC. METHODS: We performed gene expression profile analysis of formalin-fixed needle biopsy specimens from the livers of 216 patients with hepatitis C-related early-stage (Child-Pugh class A) cirrhosis who were prospectively followed up for a median of 10 years at an Italian center. We evaluated whether the 186-gene signature was associated with death, progression of cirrhosis, and development of HCC. RESULTS: Fifty-five (25%), 101 (47%), and 60 (28%) patients were classified as having poor-, intermediate-, and good-prognosis signatures, respectively. In multivariable Cox regression modeling, the poor-prognosis signature was significantly associated with death (P = .004), progression to advanced cirrhosis (P < .001), and development of HCC (P = .009). The 10-year rates of survival were 63%, 74%, and 85% and the annual incidence of HCC was 5.8%, 2.2%, and 1.5% for patients with poor-, intermediate-, and good-prognosis signatures, respectively. CONCLUSIONS: A 186-gene signature used to predict outcomes of patients with HCC is also associated with outcomes of patients with hepatitis C-related early-stage cirrhosis. This signature might be used to identify patients with cirrhosis in most need of surveillance and strategies to prevent the development of HCC.

2013-01-22 | GSE15654 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data